Herbert Wertheim Cancer Institute Research

Can we systemically reprogram the tumor microenvironment before surgery? Excited to present our work at #ASCO2026 on a novel chemokine-modulating regimen in resectable metastatic colorectal cancer. Building on years of translational research with Dr. Pawel Kalinski, this study explores reshaping the tumor microenvironment to promote anti-tumor immunity. Key findings: ✅ Safe and feasible neoadjuvant approach ✅ Increased CD8 ratios and favorable intratumoral chemokine changes These early results suggest that systemic modulation of the tumor microenvironment may strengthen future immunotherapy strategies. @ASCO @BaptistHealthSF @MiamiCancerInst @UPMC #CRC #Immunotherapy #TranslationalResearch #GIOncology

🚀 ASCO 2026 is officially underway! Excited to kick off the meeting by presenting our study on authorship trends in Phase III solid tumor clinical trials presented at #ASCO from 2015–2025. Grateful to @ASCO for selecting our work and to @AzzaSarfraz and our medical students at @FIU for their incredible contributions that made this project possible. And this is just Day 1. Our GI Cancer team at @BaptistHealthSF @MiamiCancerInst will be presenting multiple posters and research updates throughout the meeting. More to come—stay tuned! @BrainTumorDoc @BrunaPellini @ZouinaS @sawyer_bawek @nihanakkoc #ASCO2026 #Oncology #CancerResearch #ClinicalTrials #GICancer

Honored to present our research at #ASCO2026 on national discrepancies in clinical trial enrollment among patients with #BrainMetastases. 🍍 Ensuring equitable access to clinical trials remains essential to advancing cancer care. Grateful to my mentor @braintumordoc for his guidance and support! 🤜🤛

New in the May 7, 2026, issue of NEJM: Left Ventricular Unloading in High-Risk PCI (CHIP-BCIS3 trial) nej.md/4lR1vyX Daraxonrasib in RAS-Mutated Pancreatic Cancer nej.md/4f7xfhX An mRNA Seasonal Influenza Vaccine in Adults (phase 3 Fluent trial) nej.md/4nfu2z8 Ivermectin and 5% Permethrin Cream for Severe Scabies (GALE CRUSTED trial) nej.md/4tDGSsF Base Editing of HBG1 and HBG2 Promoters for SCD nej.md/3NZbo13 Subscribe to NEJM for the latest medical research: nej.md/3spfZ1z